Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin - PubMed (original) (raw)
. 2001 Jun 15;48(1):7-15.
doi: 10.1002/pros.1076.
Affiliations
- PMID: 11391682
- DOI: 10.1002/pros.1076
Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin
N Xing et al. Prostate. 2001.
Abstract
Background: Neuroendocrine (NE) differentiation may be related to the growth and progression of prostate cancer, especially androgen-insensitive tumors. Recently the over-expression of a new anti-apoptosis protein, survivin, has attracted attention for its potential implication in many human cancers. The fact that NE cells in prostate are bcl-2 negative prompted us to investigate if the prostatic NE cells over-express survivin.
Methods: Double immunohistochemical staining and immunofluorescence of chromogranin A (CgA) and survivin were performed in 57 patients with localized prostate cancer who underwent radical prostatectomy. The terminal deoxynucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end-labeling (TUNEL) method was used for apoptosis detection in three prostate cancer specimens with NE differentiation. The relationship between NE differentiation and clinicopathological characteristics, disease progression as well as patient survival, were analyzed retrospectively.
Results: It was found that NE cells in both benign and malignant prostate tissues over-expressed the anti-apoptosis protein survivin. While apoptosis was detected in non-NE epithelial cells, all NE cells were negative for apoptosis detection. During the period of follow-up, 17 (63%) of 27 patients with NE differentiation had prostate cancer progression, while 12 (40%) of 30 patients without NE differentiation had systemic prostate cancer progression. 10 (37%) of 27 patients with NE differentiation died from prostate cancer during the period of follow up, while 6 (20%) of 30 patients without NE differentiation died from prostate cancer. However, none of these characteristics reached statistical significance, probably because of the small number of cases enrolled.
Conclusions: This study discovers that all the prostatic NE cells express the new anti-apoptosis protein survivin. This provides a strong molecular basis for the hypothesis that NE cells may endure stressful conditions and escape from apoptosis. While our results suggest a trend of NE differentiation with poorer prognosis, the prognosis implication cannot be concluded due to our small sample size.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
- Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
Fixemer T, Remberger K, Bonkhoff H. Fixemer T, et al. Prostate. 2002 Oct 1;53(2):118-23. doi: 10.1002/pros.10133. Prostate. 2002. PMID: 12242726 - Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Cussenot O, et al. Prostate Suppl. 1998;8:43-51. Prostate Suppl. 1998. PMID: 9690663 Review. - The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. Mosca A, et al. J Endocrinol Invest. 2005;28(11 Suppl International):141-5. J Endocrinol Invest. 2005. PMID: 16625864 Review. - Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. Quek ML, et al. Urology. 2006 Jun;67(6):1247-52. doi: 10.1016/j.urology.2005.12.009. Epub 2006 May 12. Urology. 2006. PMID: 16697447 - Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, Mandras R, Milazzo MG, Dogliani N, De Giuli P, Fasolis G. Puccetti L, et al. Eur Urol. 2005 Aug;48(2):215-21; Discussion 221-3. doi: 10.1016/j.eururo.2005.03.018. Epub 2005 Apr 2. Eur Urol. 2005. PMID: 15992991
Cited by
- Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer.
Lee CL, Chang YH, Liu CY, Hsieh ML, Huang LK, Chu YC, Kan HC, Lin PH, Yu KJ, Chuang CK, Wu CT, Pang ST, Shao IH. Lee CL, et al. Investig Clin Urol. 2022 Sep;63(5):546-553. doi: 10.4111/icu.20210450. Investig Clin Urol. 2022. PMID: 36068000 Free PMC article. - Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.
Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J, Perner S, Pantel K, Werner S, von Amsberg G. Merkens L, et al. J Exp Clin Cancer Res. 2022 Feb 2;41(1):46. doi: 10.1186/s13046-022-02255-y. J Exp Clin Cancer Res. 2022. PMID: 35109899 Free PMC article. Review. - Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.
Rosar F, Ribbat K, Ries M, Linxweiler J, Bartholomä M, Maus S, Schreckenberger M, Ezziddin S, Khreish F. Rosar F, et al. EJNMMI Res. 2020 May 24;10(1):52. doi: 10.1186/s13550-020-00640-2. EJNMMI Res. 2020. PMID: 32449086 Free PMC article. - Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.
Faugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C, Marty V, Alexandrova K, Andree KC, Stoecklein NH, Tramalloni D, Cairo S, NgoCamus M, Nicotra C, Terstappen LWMM, Manaresi N, Lapierre V, Fizazi K, Scoazec JY, Loriot Y, Judde JG, Farace F. Faugeroux V, et al. Nat Commun. 2020 Apr 20;11(1):1884. doi: 10.1038/s41467-020-15426-2. Nat Commun. 2020. PMID: 32313004 Free PMC article. - Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
Büscheck F, Sulimankhil M, Melling N, Höflmayer D, Hube-Magg C, Simon R, Göbel C, Hinsch A, Weidemann S, Izbicki JR, Jacobsen F, Mandelkow T, Blessin NC, Möller-Koop C, Lutz F, Viehweger F, Möller K, Sauter G, Lennartz M, Burandt E, Lebok P, Minner S, Bonk S, Huland H, Graefen M, Schlomm T, Fraune C. Büscheck F, et al. Cancer Med. 2020 Feb;9(4):1409-1418. doi: 10.1002/cam4.2773. Epub 2020 Jan 1. Cancer Med. 2020. PMID: 31893572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials